Next 10 |
home / stock / ikna / ikna articles
On Tuesday, Ikena Oncology Inc (NASDAQ:IKNA) discontinued the clinical IK-930 program, the company’s TEAD1- selective Hippo pathway inhi...
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter fi...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development experti...
Thursday, Ikena Oncology Inc (NASDAQ:IKNA) announced an organizational streamlining to reallocate resources from exploratory research and...
Shares of Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) surged in pre-market trading after the company announced its foray into the Midd...
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling over 200 points on Thursday. The Dow traded down 0.71% to 33,871.77 ...
Ikena Oncology Inc (NASDAQ: IKNA) shared initial data from twenty-six patients treated in the ongoing dose escalation portion of the Phas...
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. Astra Space, Inc. (N...
News, Short Squeeze, Breakout and More Instantly...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, In...